StreetInsider.com News Articles

Form SCHEDULE 13G/A Tyra Biosciences, Inc. Filed by: NEXTECH VI ONCOLOGY SCSP

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932136.html

Form SCHEDULE 13G/A Tyra Biosciences, Inc. Filed by: NEXTECH VI ONCOLOGY SCSP

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932136.html

Form SCHEDULE 13G/A Tyra Biosciences, Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Fri, 14 Aug 2026 08:25:00 -0400

si-local-file:///var/storage/secattach/20260814/26925047.html

Form SCHEDULE 13G/A Tyra Biosciences, Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Fri, 14 Aug 2026 08:25:00 -0400

si-local-file:///var/storage/secattach/20260814/26925047.html

Tyra Biosciences (TYRA) PT Lowered to $42 at Jefferies

Wed, 05 Aug 2026 15:00:06 -0400

Jefferies analyst Stephen Volkmann lowered the price target on Tyra Biosciences (NASDAQ: TYRA) to $42.00 (from $44.00) while maintaining a Buy rating.

Tyra Biosciences, Inc. (TYRA) Misses Q2 EPS by 4c

Tue, 04 Aug 2026 17:46:45 -0400

Tyra Biosciences, Inc. (NASDAQ: TYRA) reported Q2 EPS of ($0.69), $0.04 worse than the analyst estimate of ($0.65).

For earnings history and earnings-related data on Tyra Biosciences, Inc. (TYRA) click here.

Form 424B5 Tyra Biosciences, Inc.

Tue, 04 Aug 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260804/26867604.html

Form 424B5 Tyra Biosciences, Inc.

Tue, 04 Aug 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260804/26867604.html

Form 10-Q Tyra Biosciences, Inc. For: Jun 30

Tue, 04 Aug 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260804/26867315.html

Form 10-Q Tyra Biosciences, Inc. For: Jun 30

Tue, 04 Aug 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260804/26867315.html

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tue, 04 Aug 2026 16:05:00 -0400

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -

- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5^th dose level, now expected end of Q1 2027 -

- Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy -

- Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 -

CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tue, 04 Aug 2026 16:05:00 -0400

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -

- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5^th dose level, now expected end of Q1 2027 -

- Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy -

- Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 -

CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tue, 04 Aug 2026 16:05:00 -0400

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -

- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5^th dose level, now expected end of Q1 2027 -

- Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy -

- Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 -

CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tue, 04 Aug 2026 16:05:00 -0400

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -

- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5^th dose level, now expected end of Q1 2027 -

- Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy -

- Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 -

CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tue, 04 Aug 2026 16:05:00 -0400

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -

- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5^th dose level, now expected end of Q1 2027 -

- Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy -

- Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 -

CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tue, 04 Aug 2026 16:05:00 -0400

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -

- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5^th dose level, now expected end of Q1 2027 -

- Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy -

- Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 -

CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tue, 04 Aug 2026 16:05:00 -0400

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -

- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5^th dose level, now expected end of Q1 2027 -

- Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy -

- Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 -

CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tue, 04 Aug 2026 16:05:00 -0400

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -

- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5^th dose level, now expected end of Q1 2027 -

- Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy -

- Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 -

CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tue, 04 Aug 2026 16:05:00 -0400

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -

- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5^th dose level, now expected end of Q1 2027 -

- Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy -

- Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 -

CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tue, 04 Aug 2026 16:05:00 -0400

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -

- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5^th dose level, now expected end of Q1 2027 -

- Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy -

- Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 -

CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tue, 04 Aug 2026 16:05:00 -0400

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -

- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5^th dose level, now expected end of Q1 2027 -

- Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy -

- Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 -

CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tue, 04 Aug 2026 16:05:00 -0400

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -

- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5^th dose level, now expected end of Q1 2027 -

- Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy -

- Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 -

CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tue, 04 Aug 2026 16:05:00 -0400

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -

- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5^th dose level, now expected end of Q1 2027 -

- Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy -

- Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 -

CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tue, 04 Aug 2026 16:05:00 -0400

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -

- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5^th dose level, now expected end of Q1 2027 -

- Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy -

- Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 -

CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tue, 04 Aug 2026 16:05:00 -0400

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -

- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5^th dose level, now expected end of Q1 2027 -

- Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy -

- Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 -

CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on